Case Study: Market Withdrawal
Enabling Named Patient Supply After Global Market Exit
Global Distribution. Continued Access.
The Challenge
For commercial reasons, an integrated biopharmaceutical company decided to withdraw a specialty urology product from countries outside the US and focus commercial efforts on the US market. Given there were thousands of patients who had received treatment outside the US and HCPs were wanting to continue treating patients with the product, the company faced a critical ethical and operational challenge: how to ensure uninterrupted access for existing patients, and appropriate access for new patients, without maintaining a commercial presence outside the US.
Our Approach
The company partnered with Tanner Pharma to support continued patient access following the commercial exit via a named patient sales program. Tanner enabled compliant named patient supply to ensure ethical treatment continuation and mitigate risks associated with improper use.
Tanner managed on-demand international distribution, including screening HCP requests, validating hospitals or local distributors, confirming licenses, and conducting sanctions screening. All activities were performed in full GDP compliance, ensuring products were handled and delivered according to regulatory standards. Tanner assumed financial and operational responsibility for supply, allowing the sponsor to meet ethical obligations and maintain access without infrastructure or internal oversight in withdrawn markets.
